Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Year: 2016
Type: article
Source: Annals of Oncology
Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Vall d'Hebron Hospital Universitari, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Tumour Institute of Tuscany, Ospedale di Livorno, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of California, Los Angeles, The University of Sydney, Westmead Hospital, Sarah Cannon Research Institute, University College London, Imperial College London, University of California, San Francisco, Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine, Haukeland University Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Merck, National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2342481353